Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of dioscin in preparation of Parkinson's disease protection drug

A technology of diosgenin and Parkinson's disease, which is applied in the application field of diosgenin in the preparation of Parkinson's disease protection medicine, and can solve the problems such as the related reports on the protection application of diosgenin that have not been seen.

Inactive Publication Date: 2020-03-06
DALIAN MEDICAL UNIVERSITY
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] But so far, there is no relevant report on the protection of diosgenin in Parkinson's disease and its application in the preparation of Parkinson's protection medicine.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of dioscin in preparation of Parkinson's disease protection drug
  • Application of dioscin in preparation of Parkinson's disease protection drug
  • Application of dioscin in preparation of Parkinson's disease protection drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1 Study on the protective effect of dioscin on 6-OHDA-induced PC12 cell injury

[0018] 1. MTT method to detect cell viability.

[0019] Rat pheochromocytoma cell line PC12 cells in logarithmic growth phase ( CRL-1721TM) was digested with 0.25% trypsin, the collected cell suspension was centrifuged at 1200g / min for 5min and counted, and the cells with a concentration of 1×106 cells / mL (100μL) were inoculated in a 96-well plate, cultured for 24 hours, and divided into the following: Several groups: blank group, 6-OHDA (6-hydroxydopamine) model group, model plus diosgenin administration group with different concentrations. The administration group was given different concentrations of dioscin (31.25, 62.5, 125, 250, and 500ng / ml), and each concentration was provided with 6 replicate wells. After pre-protection for 24h, 6-OHDA 400μM was given together with the model group for 6h. 10 μL of MTT (5.0 mg / ml) was added 4 hours before the end of the experiment. After ...

Embodiment 2

[0027] Example 2 Study on the protective effect of dioscin on MPTP-induced PD mice

[0028] Seventy male C57 mice aged 8-12 weeks were randomly divided into the following groups: blank group, MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) model group, MPTP modeling plus diosgenin high, medium and low dose administration groups (80, 40, 20 mg / kg) and diosgenin (80 mg / kg) simple administration group, 12 rats in each group. The blank group was intraperitoneally injected with normal saline every day for 7 consecutive days; the MPTP model group was intraperitoneally injected with 20 mg / Kg of MPTP every day, and 2 hours later was given the same amount of normal saline for 7 consecutive days; the MPTP model plus diosgenin administration group Intraperitoneal injection of MPTP 20mg / kg, 2 hours later, different doses (80, 40, 20mg / kg) of dioscin were given by intragastric administration for 7 consecutive days. After MPTP injection, dioscin was administered by intragastric administ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of dioscin in preparation of a Parkinson's disease protection drug. MTT and morphological observation prove that the dioscin has an obvious protection effect onPC12 cells induced by 6-OHDA in vitro. Meanwhile, the dioscin has an obvious down-regulation effect on the remarkable increase of the expression level of GFAP and IBA-1 caused by MPTP induction of PDmouse, which indicates that the dioscin can inhibit the activation of microglial cells and astrocytes in brain tissues. According to clinical medication requirements, the dioscin can be used as a single effective component to be prepared into a medicine, and can also be combined with other medicines to be prepared into a compound preparation. The dioscin has the advantages of being safe, free of toxic or side effect, effective, economical, practical and the like.

Description

technical field [0001] The invention relates to a new application of active ingredients of traditional Chinese medicine, in particular to the application of high-purity diosgenin in the preparation of Parkinson's disease protection medicine. Background technique [0002] Parkinson's disease (PD) is a neurodegenerative disease that commonly occurs in middle-aged and elderly people, and its important clinical symptoms include slowness of movement, abnormal posture and gait, muscle rigidity, and resting tremor. The main pathological feature is the degeneration and death of dopamine neurons in the substantia nigra pars compacta of the midbrain. The incidence of PD tends to increase with age. According to a large-scale epidemiological survey in my country, the number of PD patients in China exceeds 1.7 million. It is one of the difficult diseases identified by the World Health Organization. The current PD treatment strategy is mainly based on the replacement therapy of levodopa ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P25/16
CPCA61K31/7048A61P25/16
Inventor 彭金咏尹连红齐艳许丽娜毛章高萌孙鹏远许有威韩旭
Owner DALIAN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com